The city of Cincinnati, Ohio, currently has 3 active clinical trials seeking participants for Healthy research studies.
Study to Assess the Safety, Tolerability, Pharmacokinetics and Immunogenicity of AK006 in Healthy Subjects and Subjects With Chronic Spontaneous Urticaria
Recruiting
This is a Phase 1, randomized, double-blind, placebo-controlled, sequential, single- and multiple-ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of intravenous (IV) infusions and a single subcutaneous (SC) injection of AK006. The study will be conducted in 4 parts: a single-ascending dose part (Part A) in healthy participants, a multiple-ascending dose part (Part B) in healthy participants with an expanded cohort (Part C) in participants with... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/18/2024
Locations: Site 601-002 (Part C), Cincinnati, Ohio
Conditions: Healthy Participants, Chronic Spontaneous Urticaria
Overlapping Pain Trajectory Study
Recruiting
The goal of this observational study is to learn about spatial and temporal nociceptive filtering in adolescents with chronic overlapping pain conditions (COPCs). The main questions it aims to answer are: If spatial and temporal filtering of nociceptive information is disrupted in youth with COPCs compared with youth with localized pain conditions and healthy controls. If disrupted nociceptive processing at baseline is associated with the transition from a single localized pain condition to COP... Read More
Gender:
All
Ages:
Between 10 years and 19 years
Trial Updated:
06/07/2024
Locations: Cincinnati Children's Hospital, Cincinnati, Ohio
Conditions: Migraine, Musculoskeletal Pain, Functional Abdominal Pain Disorders, Chronic Pain, Widespread Chronic Pain, Low Back Pain, Healthy Volunteers
Safety and Tolerability of FB-001 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria
Recruiting
This Phase 1, first-in-human, randomized, double-blinded, placebo controlled study is evaluating FB-001 in healthy volunteers (Part 1) and participants diagnosed with enteric hyperoxaluria (Part 2). Eligible participants receive investigational product and undergo safety monitoring, evaluations and subsequent follow-up after investigational product administration.
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
01/23/2023
Locations: Medpace Clinical Pharmacology Unit, Cincinnati, Ohio
Conditions: Healthy, Enteric Hyperoxaluria